ImmuCell Osake

ImmuCell PEG

PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä ImmuCell (ICCC) 27.7.2026 päivämäärällä on −1,95. Edellisenä vuonna PEG-suhde (Hinta-tuotto-kasvu-suhde) oli −0,76 — muutos 158,05 % (matalampi).

PEG

−1,95

YoY

158,05%

Viimeksi päivitetty:

PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä ImmuCell on 2026 −1,95 . PEG-suhde (Hinta-tuotto-kasvu-suhde) yhtiöstä ImmuCell oli 2025 −0,76 . Se laskee 158,05% matalampi edelliseen vuoteen verrattuna.
Access this data via the Eulerpool API

ImmuCell Osakeanalyysi

Mitä ImmuCell tekee? ImmuCell Corp is an American company that specializes in the development and marketing of veterinary products for the ruminant industry. It was originally founded in the late 1970s under the name PrioGene and initially focused on the development of diagnostics for tuberculosis and brucellosis in cattle. In the 1990s, the company changed its name to ImmuCell and shifted its focus to the development of products to support animal health. ImmuCell's business model is centered around the development, manufacturing, and sale of products to improve animal health. They offer a wide range of veterinary products, including immunoassays, vaccines, antibiotics, and complementary feeds. The company aims to improve animal health with minimal impact on the environment and works closely with veterinarians and industry experts. They have divisions dedicated to diagnostics, vaccines, and antibiotics, and their products can help identify and prevent diseases in livestock. Notable products include the LBC mastitis diagnostic and the Immu-PRIME spray for preventing umbilical infections in newborn calves. ImmuCell has established itself as a leading innovator in the animal health industry and has conducted clinical studies on the efficacy of their HO-VAX product. In conclusion, ImmuCell focuses on developing and marketing products to support animal health, with a commitment to improving the well-being of livestock. ImmuCell on yksi Eurpooliin suosituimmista yhtiöistä.

Usein kysytyt kysymykset ImmuCell osakkeesta

Yhtiön ImmuCell PEG-suhde (Hinta-tuotto-kasvu-suhde) on −1,95 vuonna 2026.

Access this data via the Eulerpool API

Arvostus — ImmuCell

Kaikki tunnusluvut — ImmuCell